Emgality is a calcitonin gene-related peptide (CGRP) binding antibody studied in migraine and episodic cluster headache¹

CGRP is thought to play a central role in migraine pathogenesis¹

Elevated levels of CGRP can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP¹

• CGRP, released from the trigeminal ganglia, is elevated during migraine attacks¹
• Perivascular release of CGRP has been shown to induce vasodilation and plasma protein leakage from tissues¹
• An infusion of CGRP can induce migraine attacks in susceptible individuals, and CGRP is involved in the transmission of pain^2,3

Learn about how a CGRP antibody works

Emgality is a humanized monoclonal antibody that binds to CGRP and blocks its binding to the receptor¹

There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.¹

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

CGRP is thought to play a central role in migraine pathogenesis¹

Elevated levels of CGRP can lead to a cascade of vasodilation and pain associated with migraine attacks, as observed in preclinical studies of CGRP.¹

• CGRP, released from the trigeminal ganglia, is elevated during migraine attacks¹
• Perivascular release of CGRP has been shown to induce vasodilation and plasma protein leakage from tissues¹
• An infusion of CGRP can induce migraine attacks in susceptible individuals, and CGRP is involved in the transmission of pain^2,3

See how Emgality works

Episodic cluster headache

Discover the efficacy of Emgality for patients with migraine or episodic cluster headache

SELECT IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Emgality works differently than many other preventive medications because it was specifically developed to bind to CGRP, a substance in the brain that may play a key role in migraine^4-6

References:

1. Durham PL. CGRP-receptor antagonists—a fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073-1075.
2. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54-61.
3. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403(2):350-354.
4. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
5. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552.
6. Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281-291.